Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14666784 | 0.83 | AKR1C2 (0.49) | AHRAKR1C2AKR1C1KIF11TSHR | |
| SCHEMBL14666771 | 0.83 | KIF11 (0.45) | AHRAKR1C2AKR1C1KIF11TSHR | |
| SCHEMBL1622496 | 0.83 | AKR1C2 (0.49) | AHRAKR1C2AKR1C1KIF11TSHR | |
| SCHEMBL31156291 | 0.83 | AHR (0.58) | AHRCYP1B1AKR1C2AKR1C1KIF11 | |
| SCHEMBL24126409 | 0.82 | AKR1C2 (0.47) | AKR1C2AKR1C1KIF11CNR1PGR | |
| SCHEMBL28621673 | 0.82 | AKR1C2 (0.47) | AHRAKR1C2AKR1C1KIF11TSHR | |
| SCHEMBL799541 | 0.81 | TSHR (0.61) | AHRKIF11TSHRLMNATYR | |
| SCHEMBL18723875 | 0.79 | AKR1C2 (0.49) | AKR1C2AKR1C1KIF11CNR1CA12 | |
| SCHEMBL14670555 | 0.79 | AKR1C2 (0.45) | AKR1C2AKR1C1KIF11CNR1 | |
| SCHEMBL3423876 | 0.78 | KIF11 (0.70) | KIF11TSHRLMNATYRXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-10-31 | — | — | US | disclosed |
| US-20190099391-A1 | Glucagon Antagonists | LIGAND PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180022695-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-01-25 | — | — | US | disclosed |
| US-9783494-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783494-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170216229-A1 | GLUCAGON ANTAGONISTS | LIGAND PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170216229-A1 | GLUCAGON ANTAGONISTS | LIGAND PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20150087680-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-03-26 | — | — | US | disclosed |
| US-20150087680-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-03-26 | — | — | US | disclosed |
| US-8907103-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8907103-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20070071667-A1 | Thermal treatment of functionalized carbon nanotubes in solution to effect their functionalization | WILLIAM MARSH RICE UNIVERSITY (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030029-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | AHR 541/4885CYP1B1 1039/4885AKR1C2 483/4885 |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | AHR 541/4885CYP1B1 1039/4885AKR1C2 483/4885 |
| US-20170216229-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | AHR 582/4885CYP1B1 1429/4885AKR1C2 595/4885 |
| US-20190099391-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | AHR 582/4885CYP1B1 1429/4885AKR1C2 595/4885 |
| US-11352321-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | AHR 541/4885CYP1B1 1039/4885AKR1C2 483/4885 |
| US-20150087680-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | AHR 541/4885CYP1B1 1039/4885AKR1C2 483/4885 |
| US-20180022695-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | AHR 541/4885CYP1B1 1039/4885AKR1C2 483/4885 |
| US-10221130-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | AHR 582/4885CYP1B1 1429/4885AKR1C2 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.